Advances in Ovarian Cancer Research: From Biology to Therapeutics
Recently, substantial progress has been made in treating ovarian cancer, predominantly based on the identification of new molecular targets. For example, PARP inhibitors have been successful largely due to their efficacy in cancers that harbor BRCA mutations or evidence of deficiency in the homologous recombination DNA repair pathway. This collection of articles will address the biological discoveries leading to the next breakthroughs in ovarian cancer research and treatment. Authors are encouraged to submit research studies with translational potential, especially those that include novel biomarkers for treatment effects. This topic thus provides a framework for integrating discoveries at the bench and the bedside.
Dr. Christina M. Annunziata
Prof. Dr. Adam R. Karpf
- ovarian cancer
- translational research
- clinical trials
- tumor biology
- drug discovery
|Journal Name||Impact Factor||CiteScore||Launched Year||First Decision (median)||APC|
|5.5||8.3||2011||19.2 Days||CHF 2700|
|5.2||7.4||2009||18.2 Days||CHF 2900|
|6.0||9.0||2012||18.8 Days||CHF 2700|
|2.6||2.6||1994||18.4 Days||CHF 2200|
Preprints is a platform dedicated to making early versions of research outputs permanently available and citable. MDPI journals allow posting on preprint servers such as Preprints.org prior to publication. For more details about reprints, please visit https://www.preprints.org.